SAN DIEGO, May 16, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that Company executives will participate in the following upcoming investor conferences:

• Event: UBS Obesity Therapeutics Day
  Location: Virtual
  Date: Thursday, May 23, 2024
  Time: 12:00-12:30 PM ET

• Event: Jefferies Global Healthcare Conference
  Location: New York, NY
  Date: Thursday, June 6, 2024
  Time: 11:00-11:25 AM ET

• Event: Goldman Sachs 45th Annual Global Healthcare Conference
  Location: Miami, FL
  Date: Tuesday, June 11, 2024

A webcast of the UBS and Jefferies presentations will be available in the Investors and News section of the Ventyx website at www.ventyxbio.com. A webcast replay will also be available on this website shortly after conclusion of the event for thirty days.

About Ventyx Biosciences

Ventyx is a clinical-stage biopharmaceutical company focused on developing innovative oral medicines for patients living with autoimmune and inflammatory disorders. We believe our ability to efficiently discover and develop differentiated drug candidates will allow us to address important unmet medical need with novel oral therapies that can shift inflammation and immunology markets from injectable to oral drugs. Our current pipeline includes internally discovered clinical programs targeting NLRP3, S1P1R and TYK2, positioning us to become a leader in the development of oral immunology therapies for peripheral and neuroinflammatory diseases. Ventyx is headquartered in San Diego, California. For more information about Ventyx, please visit www.ventyxbio.com.

Investor Relations Contact
Patti Bank
Managing Director
ICR Westwicke
(415) 513-1284
This email address is being protected from spambots. You need JavaScript enabled to view it.